ClinicalTrials.gg
RecruitingNCT06174428Updated Jan 29, 2025

Validity of Viome's Oral/throat Cancer Test

An observational study in Oral and Throat Cancer, Oropharyngeal Squamous Cell Carcinoma and Oral Squamous Cell Carcinoma, sponsored by Viome. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-29.

Sponsored by Viome · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 213 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Planned enrollment
6th of 62
1,000 · median 132
Started
2025
with 60 others
Observational
62 of 1,099
11 open now
Primary completion
2026-12
later than 83 of 346 live
Registered
936th of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 6th largest by planned enrollment of the 62 observational ones that give a count, is one of 61 that started in 2025, is one of 62 observational ones, reaches primary completion later than 83 of the 346 other live ones, and was the 936th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

213 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

208 more — sign in →

All 213 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

A total of at least 1,000 participants with suspicion of cancer including at least 107 subjects who will be diagnosed with OSCC or OPSCC will be enrolled from either primary or secondary care centers in the U.S. Clinicians will use Viome collection kits to collect saliva samples from eligible patients.

Read the detailed description

This is a prospective, multi-center study. Subjects with OSCC or OPSCC will be enrolled from four primary and secondary care centers in the U.S. Study samples will be collected by the clinicians at the study sites using Viome saliva sample collection kits. Patients will continue with their current health plan and confirm diagnosis following the standard of care of surgical biopsy with histology if needed. If a biopsy is performed, the result of the biopsy will be compared with the result of the Viome kit. If no biopsy is performed, the Viome test result will be compared with the physician's assessment based on clinical judgment. Patients with a positive result from histology will not receive the results of the Viome kit, and it will not play any part in the clinical management of the patients.

03

Conditions studied

  • Oral and Throat Cancer
  • Oropharyngeal Squamous Cell Carcinoma
  • Oral Squamous Cell Carcinoma

Keywords

  • OSCC
  • OPSCC
  • Oral Cancer
  • Throat cancer
  • Oral and Throat cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will comprise patients who attend (1) a primary care center (typically dentist offices) and are identified with a suspicion of cancer based on a clinical presentation or (2) a secondary care center (typically hospitals) following the finding of a suspicious lesion or symptom. Secondary care centers include clinical sites where specialists such as oncologists or oral and maxillofacial surgeons (also called head and neck surgeons) perform visual and tactile oral examinations and biopsies to detect oral cancer. They are also known as ear, nose, and throat (ENT) doctors or otolaryngologists.

Women or minorities are not excluded from this study. In order to calculate an estimated number of samples in each demographic category we performed stratified random sampling. We used the SEER Program to calculate oral and throat cancer prevalence for each of the demographic categories.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated prior to any study-specific procedures are performed
  • Willing and able to follow the study instructions, as described in the recruitment letter
  • Adults (18 years old or older)
  • Suspicion of OSCC or OPSCC on clinical presentation by a clinician

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Use of fertility enhancing medications
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Oral Squamous Cell Carcinoma (OSCC)

    OSCC case cohort will consist of patients with Oral Squamous Cell Carcinoma (all stages, locations), recruited from either primary or secondary care.

    Device: Oral/Throat cancer test

  • Oropharyngeal Squamous Cell Carcinoma (OPSCC)

    OPSCC case cohort will consist of patients with Oral Squamous Cell Carcinoma (all stages, locations), recruited from either primary or secondary care.

    Device: Oral/Throat cancer test

  • Cancer-free

    Participants will be recruited following clinical adjudication with self-reported confirmation of no cancer and from primary and secondary care facilities.

    Device: Oral/Throat cancer test

Interventions

  • DeviceOral/Throat cancer test

    The Oral/Throat cancer test is intended for the qualitative detection of molecular features (human genes, microbial species and functions) associated with Oral Squamous Cell Carcinoma (OSCC) or OroPharyngeal Squamous Cell Carcinoma (OPSCC) in saliva samples from adults with a suspicion of cancer. A positive result from CDOT may indicate the presence of OSCC or OPSCC. The device is intended as a diagnostic aid for clinicians when assessing patients with suspected OSCC or OPSCC who may benefit from follow-up diagnosis and treatment. The device is not intended for a definitive diagnosis.

06

What researchers measure

Primary outcomes

  1. Sensitivity

    Oral/Throat cancer test's ability to designate an individual with disease as positive

    Time frame: Through study completion, an average of 18 months

  2. Specificity

    Oral/Throat cancer test's ability to designate an individual who does not have a disease as negative

    Time frame: Through study completion, an average of 18 months

  3. Positive Post Test Probability (PPV)

    The probability of having the target condition if the test falls out positive

    Time frame: Through study completion, an average of 18 months

  4. Negative Post Test Probability (NPV)

    The probability of having the target condition if the test falls out negative

    Time frame: Through study completion, an average of 18 months

Secondary outcomes

  1. Sensitivity by care center (primary and secondary)

    Oral/Throat cancer test's ability to designate an individual with disease as positive

    Time frame: Through study completion, an average of 18 months

  2. Sensitivity by age

    Oral/Throat cancer test's ability to designate an individual with disease as positive

    Time frame: Through study completion, an average of 18 months

  3. Sensitivity by sex

    Oral/Throat cancer test's ability to designate an individual with disease as positive

    Time frame: Through study completion, an average of 18 months

  4. Sensitivity by race

    Oral/Throat cancer test's ability to designate an individual with disease as positive

    Time frame: Through study completion, an average of 18 months

  5. Sensitivity by smoking history

    Oral/Throat cancer test's ability to designate an individual with disease as positive

    Time frame: Through study completion, an average of 18 months

  6. Sensitivity by oral cancer type (OSCC or OPSCC)

    One measure post treatment

    Time frame: Through study completion, an average of 18 months

  7. Sensitivity by disease stage (I, II, III, and IV)

    Oral/Throat cancer test's ability to designate an individual with disease as positive

    Time frame: Through study completion, an average of 18 months

  8. Sensitivity by metastasis

    Oral/Throat cancer test's ability to designate an individual with disease as positive

    Time frame: Through study completion, an average of 18 months

  9. Sensitivity by HPV status

    Oral/Throat cancer test's ability to designate an individual with disease as positive

    Time frame: Through study completion, an average of 18 months

  10. Sensitivity by recurrent cancer

    Oral/Throat cancer test's ability to designate an individual with disease as positive

    Time frame: Through study completion, an average of 18 months

  11. Specificity by care center (primary and secondary)

    One measure post treatment

    Time frame: Through study completion, an average of 18 months

  12. Specificity by age

    Oral/Throat cancer test's ability to designate an individual who does not have a disease as negative

    Time frame: Through study completion, an average of 18 months

  13. Specificity by sex

    Oral/Throat cancer test's ability to designate an individual who does not have a disease as negative

    Time frame: Through study completion, an average of 18 months

  14. Specificity by race

    Oral/Throat cancer test's ability to designate an individual who does not have a disease as negative

    Time frame: Through study completion, an average of 18 months

  15. Specificity by smoking history

    Oral/Throat cancer test's ability to designate an individual who does not have a disease as negative

    Time frame: Through study completion, an average of 18 months

  16. Specificity by oral cancer type (OSCC or OPSCC)

    Oral/Throat cancer test's ability to designate an individual who does not have a disease as negative

    Time frame: Through study completion, an average of 18 months

  17. Specificity by disease stage (I, II, III, and IV)

    Oral/Throat cancer test's ability to designate an individual who does not have a disease as negative

    Time frame: Through study completion, an average of 18 months

  18. Specificity by metastasis

    Oral/Throat cancer test's ability to designate an individual who does not have a disease as negative

    Time frame: Through study completion, an average of 18 months

  19. Specificity by HPV status

    Oral/Throat cancer test's ability to designate an individual who does not have a disease as negative

    Time frame: Through study completion, an average of 18 months

  20. Specificity by recurrent cancer

    Oral/Throat cancer test's ability to designate an individual who does not have a disease as negative

    Time frame: Through study completion, an average of 18 months

07

Study locations

2 of 2 sites recruiting
  • Missouri School of Dentistry & Oral Health
    St. Louis, Missouri 63104, United States
    Recruiting
  • UTHSC
    Memphis, Tennessee 38163, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

Of 117 observational studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 77 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 132. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2023
First posted
Dec 18, 2023
StartActual
Jan 27, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06174428
Lead sponsor
Viome
Responsible party
Sponsor
First posted
Dec 18, 2023
Start date
Jan 27, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 29, 2025

Study contacts

Mory Mehrtash
Contact
studies@viome.com
425-300-6933
Momchilo Vuyisich
Contact
studies@viome.com
425-300-6933
Cristina Julian
principal investigator · Viome

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion